ArticleScientific reports2025
Biochemical characterisation and in vitro mitigation of Xanthomonas citri pv. punicae, causing bacterial blight in pomegranate, using antibiotics and copper compounds.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering the potential antagonistic activity of Bacillus velezensis GNB3-7 against Astragalus mongholicus root rot.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial blight, caused by Xanthomonas citri pv. punicae (Xcp), severely impacts the global pomegranate industry, with alarming yield losses up to 80%. This pathogen becomes a glitch in the pomegranate industry, leading to reduced commercial pockets globally, especially in Pakistan. The objective of this study was to conduct biochemical characterisation and in vitro evaluation of copper compounds and antibiotics against Xcp, for optimal fruit quality and yield. The pathogen was isolated from infected tissues of the pomegranate, and various biochemical tests were performed to identify the bacteria. Pathogenicity was confirmed using the pin-prick and infiltration method on cv. Golden. The in vitro efficacy of antibiotics and copper compounds was assessed using the disk diffusion method against Xcp. The pathogen was aseptically cultured via the streak plate method, and disks impregnated with different chemical concentrations were placed on solidified media. A control disk was treated with sterile water containing 1% v/v surfactant. Plates were incubated at 28 ± 2 °C for 48 and 72 h to observe bacterial growth inhibition. Biochemical analysis showed positive results for the oxidase test, catalase test, KOH solubility test, gelatin liquefaction, and starch hydrolysis test, while Gram staining was negative. Antibacterial efficacy was determined by measuring inhibition zones after 48 and 72 h of incubation. The highest inhibition zones, measuring 29.55 mm and 37.73 mm at 48 and 72 h, respectively, were recorded with 550 µg/ml oxytetracycline hydrochloride, followed by streptomycin sulfate (550 µg/ml) with zones of 29.12 mm and 32.42 mm. In contrast, copper-based compounds, particularly copper sulfate (2000 µg/ml), exhibited the lowest inhibition, with zones of 8.85 mm and 8.86 mm at the respective time intervals. A comparative analysis demonstrated that antibiotics showed outstanding and prodigious results compared to copper compounds. The results of this experiment demonstrate the effectiveness of oxytetracycline hydrochloride and streptomycin sulfate in inhibiting the radial growth of Xcp under controlled conditions. Furthermore, changes in dosage/concentration, time of application, and field application method may help researchers with field-oriented results in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.